Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 7, 2025 (2 years ago)

Levothyroxine Sodium Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Super-Potent Drug: Out of specification potency results were obtained.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-445-20.

Affected NDC 51079-0445-20

Compare with the code on your package — it is the most precise check available.

Drug: Levothyroxine Category: Thyroid Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Levothyroxine Sodium
NDC 51079-0445
150 ug/1 Tablet
Oral
Mylan Institutional Inc. Rx
Recalling firm
Mylan Institutional, Inc.
NDC code
51079-445-20
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0290-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Levothyroxine recalls

See all

Other recalls by Mylan Institutional, Inc.

All 2025 recalls